Telehealth founder or operator

Start with these three chapters

Map service responsibilities, understand the product pathway, then review patient-facing claims.

1. Understand the service behind the screen
2. 503A and 503B: understand the pathway before the product
3. Accurate patient-facing claims

Then use the reading path and books for more depth, and complete the learning worksheet to record what you found.

Know which product the evidence describes

A molecule name is a starting point, not a complete product description. Record the active ingredient, chemical form, formulation, route, manufacturer or compounder and the document date. Products using similar names may differ in ways that matter. A result for one preparation does not automatically establish the performance of another.

FDA approval concerns a particular drug product and its authorized labeling. A facility registration, product listing or National Drug Code does not mean FDA has approved the product. A company can have legitimate paperwork for one activity without every product or claim being authorized.

Compounded drugs are prepared under a different framework and are not FDA-approved. They can serve particular patient needs, but FDA does not review each compounded product for safety, effectiveness and quality before marketing in the way it reviews approved medicines. The 503A and 503B pathways have different conditions, explained below.

Investigational means a product or use is being studied; it does not mean success is established. Research-use labeling concerns a claimed purpose and cannot establish suitability for human use. Keep regulatory status, analytical quality and clinical evidence as three separate entries. None can substitute for the other two.

Build a simple comparison: what the paper studied, what the official label describes, and what the current document or service names. Mark missing information rather than filling it with a brand assumption. This comparison is useful for a patient preparing questions and for a professional reviewing a brochure.

Understand the service behind the screen

A telehealth service includes more than the video call. Map assessment, clinical decisions, prescriptions where applicable, dispensing, delivery questions, records and continuing care. Identify which organization and professional are responsible for each step. A convenient interface does not explain those relationships by itself.

For U.S. cross-state care, patient location and the clinician’s profession matter. HHS describes several possible licensure pathways; requirements differ by state. Record where the patient will be during the visit and consult the relevant official licensing source. A platform operating nationally does not demonstrate that every clinician can practice everywhere.

Before a visit, check how to connect, how to obtain accessibility or language assistance, what records to provide and how to reconnect if the technology fails. Ask about privacy and whether a private setting is available. Clarify costs, coverage and ongoing commitments separately from questions about clinical appropriateness.

For an operator, turn the patient journey into a responsibility record: the responsible party, patient-facing contact, handoff information and unresolved question at each stage. Include how a person can obtain records, raise a concern and reach clinical follow-up. This educational map helps reveal omissions; it is not an operating authorization or a substitute for jurisdiction-specific review.

Remote care has limits. A service should be able to explain which situations need examination, testing or urgent in-person assessment. The user-facing explanation should identify a practical contact route and the service’s boundaries, rather than leaving the patient with only an automated purchase or renewal screen.

503A and 503B: understand the pathway before the product

Compounding means preparing a medicine for particular needs by combining, mixing or altering ingredients. In the United States, sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act establish different conditions for exemptions from certain federal requirements. They are not product-approval programs. A compounded medicine does not become FDA-approved because a pharmacy holds a license or an outsourcing facility appears in a registration database.

Section 503A concerns compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician. Its prescription condition concerns an identified individual patient. Limited anticipatory compounding can occur under specified conditions before a prescription arrives, but that is not unrestricted authority to supply unassigned office stock. When all applicable conditions are met, the product can qualify for exemptions from premarket approval, adequate-directions labeling and federal current good manufacturing practice requirements. Other requirements still apply.

Section 503B concerns outsourcing facilities, where compounding occurs by or under the direct supervision of a licensed pharmacist. These facilities remain subject to current good manufacturing practice, often abbreviated CGMP. They may obtain individual prescriptions or supply healthcare providers with office stock: medicine held before a particular patient needs it. FDA conducts risk-based inspections, and reporting obligations apply. Registration is not a guarantee that every preparation, practice or transaction complies.

Bulk ingredients have separate eligibility gates. Under 503A, FDA describes an applicable USP/NF monograph route; when no applicable monograph exists, a component-of-an-approved-drug route; or, when neither applies, inclusion on the 503A bulks list. Under 503B, a substance generally needs inclusion on the clinical-need bulks list, or the resulting drug must be on the shortage list at compounding, distribution and dispensing. A monograph is a published quality standard, not approval of every preparation made from the ingredient.

A valid certificate of analysis and manufacture by an FDA-registered establishment are additional bulk-substance conditions, not substitutes for eligibility. Interim enforcement policies are also distinct from the statutory lists: nomination or Category 1 status is not final list inclusion. Other limits, including restrictions involving essentially copies of available medicines, still need attention. Review the specific product, pathway and date rather than assuming that a familiar ingredient or a national shortage headline answers everything.

503A status as of October 31, 2026: interim Categories 1, 2 and 3 are not the final 503A bulks list. Category 1 concerns adequately supported nominations under evaluation; Category 2 identifies significant safety concerns; Category 3 concerns inadequate nomination support. Removal from Category 2 does not itself establish eligibility. An advisory-committee recommendation is nonbinding advice, not list inclusion. Addition to the final list requires FDA rulemaking; other 503A conditions still apply. Read the category record, committee record and final rule separately rather than treating one as a substitute for another.

Status-note sources checked October 31, 2026; this is not a claim that every retained source was re-reviewed.

What “gray market” leaves unexplained

“Gray market” is a loose conversational label, not a quality grade or a legal conclusion. It can blur several different issues: an unapproved product promoted for human use, an authentic product outside a documented supply chain, a counterfeit identity, misleading research labeling, or a preparation that does not meet a compounding pathway’s conditions. Name the actual question before deciding what a document or testimonial proves.

A research-use statement describes a claimed purpose; it does not automatically settle intended use. In a March 31, 2026 warning letter to Gram Peptides, FDA explained that website evidence established intended human use despite research-only and not-for-human-consumption disclaimers. This is an example of FDA’s stated enforcement findings, not a final court judgment or a claim about the company’s later status. The broader lesson is to read the surrounding claims and presentation, not a disclaimer in isolation.

Counterfeit and unapproved are also different concepts. Counterfeit identity concerns a product falsely represented as authentic. Unapproved status concerns the absence of applicable approval. Lawfully compounded medicines are themselves not FDA-approved, so “unapproved” alone does not describe every applicable legal condition. Conversely, calling something compounded does not establish that it meets those conditions. Classification requires the exact product, source, claims and regulatory context.

Chemical names require precision. On its current GLP-1 concerns page, FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law. The same page distinguishes semaglutide sodium and acetate from the active ingredient in approved medicines and says the agency is unaware of a lawful basis for their compounding use. These are product-specific statements, reviewed October 31, 2026; do not generalize them to every peptide, salt or jurisdiction.

A separate FDA clarification dated April 1, 2026 discusses restrictions on preparations that are essentially copies of commercially available drugs. It explains that adding another active ingredient does not automatically avoid those restrictions. That dated statement should remain dated: it is not an independently checked live shortage-database result. An April 30, 2026 announcement proposing exclusion of three GLP-1 substances from the 503B bulks list was a proposal, not a final decision.

For an educational review, record exactly what is known: the named item, original source, date, claimed use and unresolved identity or quality questions. Distinguish a reported adverse event from proven causation and a compelling anecdote from a controlled study. Neither a disclaimer nor a dramatic personal story turns an uncertain product into a verified clinical option.

Explain a claim with its evidence attached

A reader receives a message from the complete presentation: headline, image, testimonial, spoken words and qualifications. Write down the actual impression before judging the evidence. A document titled “education” can still communicate a product benefit or sales claim.

Keep a claim ledger with the exact wording, intended audience, primary source and relevant limits. Record the population, product, outcome and date. Attach a decision: supported as written, needs narrowing, or unanswered. This makes review repeatable when a sentence moves from a website to a printed handout.

Use plain language without removing uncertainty. Explain an unfamiliar term when it first appears. Put a consequential limitation beside the claim it qualifies. A small disclaimer elsewhere cannot repair an unsupported headline. Separate community reports from controlled evidence and company statements from independently established findings.

Give each document a content owner, version and review date. Preserve sources and consequential limitations when adapting it for another audience. Keep a change record so later readers can identify which claim changed and why.

Changed claims about presentation checked against FTC guidance October 31, 2026.

Where to report a problem and how to check a pharmacy

FDA MedWatch accepts reports of adverse events and product-quality problems. Record the product name, manufacturer or compounder, lot if available, dates, what happened and relevant packaging or photographs; distinguish what you observed from what you suspect caused it. A report communicates a concern and does not itself prove causation.

Use FDA BeSafeRx to learn how to evaluate an online pharmacy, then follow FDA’s state-pharmacy directory to the relevant board’s license lookup. Match the legal name and address, check the current license record and contact the board when an entry is unclear. A license lookup and a product-approval record answer different questions.

Sources for this addition checked October 31, 2026.

Accurate patient-facing claims

On March 3, 2026, FDA announced warning letters to 30 telehealth companies concerning misleading promotion of compounded GLP-1 products. Its examples included implying sameness with approved medicines and branding that obscured who compounded the product. The announcement date is distinct from individual letter dates.

The GoodGirlRX letter, dated February 20 and posted March 3, challenged imagery suggesting the telehealth company was the compounder and statements implying FDA approval of compounded products. Use this record to examine attribution and product status, rather than treating it as a verdict on every telehealth service. Warning letters describe FDA’s concerns at that time; later responses or actions may change the record.

Sources for this addition checked October 31, 2026.

Reading path and books

Continue in the Church Library

Choose the depth that fits your background. Library entries include reading options and affiliate disclosures where applicable.

Browse all Library rooms →

Examples in practice

These examples identify published resources and their uses; they are not evaluated services.

Questions and explanations

Glossary

Comparator

The reference group or intervention against which an outcome is compared, such as placebo or another treatment.

Endpoint

An outcome defined for a study. A biological measurement and a patient-important outcome are not necessarily the same thing.

Formulation

The composition and presentation of a product, including ingredients beyond the active substance.

Adverse event

An unwanted medical occurrence during observation; occurrence does not itself establish a causal connection to treatment.

Investigational

Under investigation. This describes research status, not proof of safety or benefit.

API

Active pharmaceutical ingredient: the substance intended to provide a medicine’s pharmacological activity. An API is not the same as a finished medicine.

503A / 503B

Different U.S. statutory pathways for qualifying compounded drugs. Neither makes a compounded drug FDA-approved.

CGMP

Current good manufacturing practice: requirements for manufacturing controls and quality. The applicable framework depends on the activity and product.

Gray market

An informal description of uncertain or unauthorized distribution channels, not a regulatory approval category.